<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OL</journal-id>
<journal-title-group>
<journal-title>Oncology Letters</journal-title></journal-title-group>
<issn pub-type="ppub">1792-1074</issn>
<issn pub-type="epub">1792-1082</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/ol.2010.180</article-id>
<article-id pub-id-type="publisher-id">ol-01-06-0951</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject></subj-group></article-categories>
<title-group>
<article-title>Insertion of the 3&#x02032; ABL region into the long arm of chromosome 1 in a Philadelphia chromosome-negative chronic myeloid leukemia case</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>AL-ACHKAR</surname><given-names>WALID</given-names></name><xref rid="af1-ol-01-06-0951" ref-type="aff">1</xref><xref ref-type="corresp" rid="c1-ol-01-06-0951"/></contrib>
<contrib contrib-type="author">
<name><surname>LIEHR</surname><given-names>THOMAS</given-names></name><xref rid="af2-ol-01-06-0951" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author">
<name><surname>WAFA</surname><given-names>ABDULSAMAD</given-names></name><xref rid="af1-ol-01-06-0951" ref-type="aff">1</xref></contrib></contrib-group>
<aff id="af1-ol-01-06-0951">
<label>1</label>Molecular Biology and Biotechnology Department, Human Genetics Division, Atomic Energy Commission of Syria, Damascus, Syria</aff>
<aff id="af2-ol-01-06-0951">
<label>2</label>Jena University Hospital, Institute of Human Genetics and Anthropology, Jena, Germany</aff>
<author-notes>
<corresp id="c1-ol-01-06-0951"><italic>Correspondence to:</italic> Dr Walid Al Achkar, Molecular Biology and Biotechnology Department, Human Genetics Division, Atomic Energy Commission of Syria, P.O. Box 6091, Damascus, Syria, E-mail: <email>ascientific@aec.org.sy</email></corresp></author-notes>
<pub-date pub-type="ppub">
<month>11</month>
<year>2010</year></pub-date>
<pub-date pub-type="epub">
<day>23</day>
<month>9</month>
<year>2010</year></pub-date>
<volume>1</volume>
<issue>6</issue>
<fpage>951</fpage>
<lpage>954</lpage>
<history>
<date date-type="received">
<day>09</day>
<month>6</month>
<year>2010</year></date>
<date date-type="accepted">
<day>18</day>
<month>8</month>
<year>2010</year></date></history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2010, Spandidos Publications</copyright-statement>
<copyright-year>2010</copyright-year></permissions>
<abstract>
<p>Chronic myeloid leukemia (CML) is a pluripotent hematopoietic stem cell disorder almost always characterized by the presence of the Philadelphia chromosome (Ph), usually due to t(9;22)(q34;q11). The presence of Ph results in the formation of the BCR/ABL fusion gene, which is a constitutively activated tyrosine kinase. Approximately 1&#x00025; of CML patients appear to have a Ph-negative karyotype but carry a cryptic BCR/ABL fusion that can be located by fluorescence <italic>in situ</italic> hybridization (FISH) at chromosome 22q11, 9q34 or a third chromosome. This study investigated a rare Ph-negative CML case with insertion of the 3&#x02032; ABL region into the long arm of derivative chromosome 1 but lacking the 5&#x02032; BCR region on der(22).</p></abstract>
<kwd-group>
<kwd>Philadelphia chromosome negative</kwd>
<kwd>chronic myeloid leukemia</kwd>
<kwd>BCR/ABL rearrangement</kwd>
<kwd>fluorescence <italic>in situ</italic> hybridization</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Chronic myeloid leukemia (CML) is a pluripotent hematopoietic stem cell disorder defined by expression of the BCR/ABL fusion gene, a constitutively activated tyrosine kinase, harbored by the Philadelphia chromosome (Ph), which is the result of a t(9;22)(q34;q11) or a related variant translocation (<xref rid="b1-ol-01-06-0951" ref-type="bibr">1</xref>). In approximately 1&#x00025; of CML patients, bone marrow cells appear to be Ph-negative by G-banding, although the BCR/ABL fusion gene can be identified by molecular means and can be located by fluorescence <italic>in situ</italic> hybridization (FISH) on chromosome 22q11, 9q34 or even a third chromosome (<xref rid="b2-ol-01-06-0951" ref-type="bibr">2</xref>&#x02013;<xref rid="b5-ol-01-06-0951" ref-type="bibr">5</xref>). Cases of Ph-negative BCR/ABL-positive CML with the chimeric gene present on derivative chromosome der(22), as in the majority of CML cases, or alternatively on der(<xref rid="b9-ol-01-06-0951" ref-type="bibr">9</xref>) appear to have the same clinical and molecular characteristics as Ph-positive patients. However, a worse prognosis associated with the location of BCR/ABL on der(<xref rid="b9-ol-01-06-0951" ref-type="bibr">9</xref>) was previously noted (<xref rid="b6-ol-01-06-0951" ref-type="bibr">6</xref>&#x02013;<xref rid="b9-ol-01-06-0951" ref-type="bibr">9</xref>).</p>
<p>The biology and clinical significance of genetic rearrangements in Ph-negative BCR/ABL-positive disease was evaluated following initial descriptions (<xref rid="b2-ol-01-06-0951" ref-type="bibr">2</xref>&#x02013;<xref rid="b5-ol-01-06-0951" ref-type="bibr">5</xref>). Two mechanisms involved in the formation of the chimeric gene in masked Ph-positive cells have been postulated: insertion of ABL into the BCR region (or vice versa), or by a multiple-step model where a classical t(9;22) is followed by translocation of the two products and/or another autosome, thereby restoring the normal chromosome morphology. In both instances, more than the 2 breaks associated with classical t(9;22) are implicated (<xref rid="b10-ol-01-06-0951" ref-type="bibr">10</xref>).</p>
<p>This study investigated a rare CML case, Ph-negative, with an insertion of the 3&#x02032; ABL region into the long arm of derivative chromosome 1 and lacking the 5&#x02032; BCR region on der(22).</p></sec>
<sec sec-type="methods">
<title>Materials and methods</title>
<sec>
<title>Case report</title>
<p>In July 2005, a female patient, 31 years of age, presented for the first time with a whole blood cell count (WBC) of 35.07&#x000D7;10<sup>9</sup>/l (72.3&#x00025; neutrophils, 13&#x00025; lymphocytes, 1.16&#x00025; eosinophiles, 5.7&#x00025; monocytes, 4.1&#x00025; basophiles and 3.6&#x00025; immature cells). The platelet count was 381&#x000D7;10<sup>9</sup>/l, and the hemoglobin level was 9.8 g/dl. A physical examination showed no splenomegaly, although loss of weight was noted. Results of a chromosome analysis using banding cytogenetics showed a karyotype in concordance with the clinical diagnosis of CML in the chronic phase (CP). The patient was treated with hydroxyurea (1500 mg daily dose) for a duration of two years and eleven months. In June 2008, the patient presented for the second time with a WBC count of 20.86&#x000D7;10<sup>9</sup>/l (73&#x00025; neutrophils, 15.2&#x00025; lymphocytes, 1.2&#x00025; eosinophiles, 5.3&#x00025; monocytes and 5.3&#x00025; basophiles). The platelet count was 497&#x000D7;10<sup>9</sup>/l, and the hemoglobin level was 12.9 g/dl. Serum lactate dehydrogenase (LDH) was 1274 U/l (normal up to 460 U/l), serum alanine aminotransferase was 54 U/l (normal up to 40 U/l) and serum aspartate aminotransferase was 41 U/l (normal up to 40 U/l). The patient was treated with hydroxyurea (1500 mg daily dose), but was subsequently lost during follow-up.</p></sec>
<sec>
<title>Banding cytogenetics</title>
<p>Banding cytogenetics using the GTG-method was conducted according to standard procedures (<xref rid="b11-ol-01-06-0951" ref-type="bibr">11</xref>). A total of 20 metaphases derived from the unstimulated bone marrow of the patient were analyzed individually. Karyotypes were described according to the International System for Human Cytogenetic Nomenclature (<xref rid="b12-ol-01-06-0951" ref-type="bibr">12</xref>).</p></sec>
<sec>
<title>Fluorescence in situ hybridization</title>
<p>FISH using BCR/ABL dual-color dual fusion translocation probe (Abbott Molecular/Vysis, USA) and whole chromosome painting (wcp) probe for chromosomes 1, 9 and 22 (MetaSystems, Germany) were applied as previously described (<xref rid="b11-ol-01-06-0951" ref-type="bibr">11</xref>). A total of 50 metaphase spreads were analyzed, each using a fluorescence microscope (Axio Imager.Z1 mot; Zeiss) equipped with appropriate filter sets to discriminate between a maximum of five fluorochromes and the counterstain DAPI (4&#x02032;,6-diamino-2-phenylindole). Image capturing and processing were carried out using an image analysis system (MetaSystems, Altlussheim, Germany).</p></sec></sec>
<sec sec-type="results">
<title>Results</title>
<p>A normal karyotype 46,XX was determined in the GTG-banding (<xref rid="f1-ol-01-06-0951" ref-type="fig">Fig. 1</xref>) and was further studied by molecular cytogenetics (<xref rid="f2-ol-01-06-0951" ref-type="fig">Fig. 2</xref>). Dual-color-FISH using probes specific for BCR and ABL revealed that the BCR/ABL-translocation fusion gene was absent on der(22). However, the presence of the ABL/BCR-translocation fusion gene on der(<xref rid="b9-ol-01-06-0951" ref-type="bibr">9</xref>), insertion of the 3&#x02032; ABL region on der(<xref rid="b1-ol-01-06-0951" ref-type="bibr">1</xref>) and lack of the 5&#x02032; BCR region on der(22) were noted (<xref rid="f2-ol-01-06-0951" ref-type="fig">Fig. 2A and B</xref>). Moreover, FISH using wcp1, wcp9 and wcp22 probes did not show a translocation between chromosome 1 and 9 or chromosome 1 and 22 (<xref rid="f2-ol-01-06-0951" ref-type="fig">Fig. 2C and D</xref>). Thus, the result obtained was: 46,XX,ins(1;9)(q21.3;q34q34),ins(9;22)(q34;q11q11),del(22)(q11q11).</p></sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>The present study identified one additional chromosomal alteration, insertion of the 3&#x02032; ABL region on der(<xref rid="b1-ol-01-06-0951" ref-type="bibr">1</xref>), in a Ph-negative BCR/ABL-positive CML-CP case. To the best of our knowledge, the insertion of the ABL region into der(<xref rid="b1-ol-01-06-0951" ref-type="bibr">1</xref>) has never been described in CML (<xref rid="b13-ol-01-06-0951" ref-type="bibr">13</xref>).</p>
<p>According to the literature, two alternative mechanisms were postulated to elucidate the formation of a fusion gene in Ph-negative BCR/ABL-positive CML patients (<xref rid="b10-ol-01-06-0951" ref-type="bibr">10</xref>,<xref rid="b14-ol-01-06-0951" ref-type="bibr">14</xref>). The first mechanism involves a one-step model where BCR/ABL results from a simple insertion of either 3&#x02032; ABL1 into BCR or 5&#x02032; BCR into ABL after three genomic breaks. The second mechanism is a multiple-step model involving an initial classical t(9;22)(q34;q11) followed by a second translocation of the two products and/or a third chromosome, requiring a minimum of 4 genomic breaks (<xref rid="b14-ol-01-06-0951" ref-type="bibr">14</xref>).</p>
<p>In the present case, FISH results led to the conclusion that insertion of 5&#x02032; BCR sequences within the ABL gene transpired while 3&#x02032; BCR sequences remained on chromosome 22 (<xref rid="f3-ol-01-06-0951" ref-type="fig">Fig. 3</xref>). Previous studies on other Ph-negative patients with the BCR-ABL fusion gene at 9q34 also proposed the insertion of chromosome 22 sequences into chromosome 9 as the more likely mechanism, as opposed to one involving two consecutive translocations. This event appears more likely as it requires only two breaks at chromosome 22 and one at chromosome 9 instead of a total of four breaks involved in the double-consecutive translocation (<xref rid="b15-ol-01-06-0951" ref-type="bibr">15</xref>).</p>
<p>A second event, insertion of 3&#x02032; ABL sequences on der(<xref rid="b1-ol-01-06-0951" ref-type="bibr">1</xref>), possibly shifted ABL from der(22) to the long arm of chromosome 1. The 5&#x02032; region of the BCR gene was deleted on der(22). The patient presented with CML-CP. Thus, the second event may be the evolution of a Ph-negative karyotype.</p>
<p>In conclusion, regarding the karyotype observed in the present case with the insertion mechanism, a minimum of five breaks are required; one on chromosome 1, two on chromosome 9 and two on chromosome 22, to explain the insertion and deletion.</p></sec></body>
<back>
<ack>
<title>Acknowledgements</title>
<p>We thank Professor I. Othman, Director General of the Atomic Energy Commission of Syria (AECS) and Dr N. Mirali, Head of the Molecular Biology and Biotechnology Department for their support. This work was supported by the Syrian Atomic Energy Commission, in part, by the Stefan-Morsch-Stiftung, Monika-Kutzner-Stiftung and the DAAD (D/07/09624).</p></ack>
<ref-list>
<title>References</title>
<ref id="b1-ol-01-06-0951"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melo</surname><given-names>JV</given-names></name><name><surname>Barnes</surname><given-names>DJ</given-names></name></person-group><article-title>Chronic myeloid leukaemia as a model of disease evolution in human cancer</article-title><source>Nat Rev Cancer</source><volume>7</volume><fpage>441</fpage><lpage>453</lpage><year>2007</year></element-citation></ref>
<ref id="b2-ol-01-06-0951"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagemeijer</surname><given-names>A</given-names></name><name><surname>de Klein</surname><given-names>A</given-names></name><name><surname>Godde-Salz</surname><given-names>E</given-names></name><name><surname>Turc-Carel</surname><given-names>C</given-names></name><name><surname>Smit</surname><given-names>EM</given-names></name><name><surname>van Agthoven</surname><given-names>AJ</given-names></name><name><surname>Grosveld</surname><given-names>GC</given-names></name></person-group><article-title>Translocation of c-abl to &#x02018;masked&#x02019; Ph in chronic myeloid leukemia</article-title><source>Cancer Genet Cytogenet</source><volume>18</volume><fpage>95</fpage><lpage>104</lpage><year>1985</year></element-citation></ref>
<ref id="b3-ol-01-06-0951"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>CM</given-names></name><name><surname>Reeve</surname><given-names>AE</given-names></name><name><surname>Fitzgerald</surname><given-names>PH</given-names></name><name><surname>Hollings</surname><given-names>PE</given-names></name><name><surname>Beard</surname><given-names>ME</given-names></name><name><surname>Heaton</surname><given-names>DC</given-names></name></person-group><article-title>Genomic diversity correlates with clinical variation in Ph&#x02019;-negative chronic myeloid leukaemia</article-title><source>Nature</source><volume>320</volume><fpage>281</fpage><lpage>283</lpage><year>1986</year></element-citation></ref>
<ref id="b4-ol-01-06-0951"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagemeijer</surname><given-names>A</given-names></name><name><surname>Buijs</surname><given-names>A</given-names></name><name><surname>Smit</surname><given-names>E</given-names></name><name><surname>Janssen</surname><given-names>B</given-names></name><name><surname>Creemers</surname><given-names>GJ</given-names></name><name><surname>van der Plas</surname><given-names>D</given-names></name><name><surname>Grosveld</surname><given-names>G</given-names></name></person-group><article-title>Translocation of BCR to chromosome 9: a new cytogenetic variant detected by FISH in two Ph-negative, BCR-positive patients with chronic myeloid leukemia</article-title><source>Genes Chromosomes Cancer</source><volume>8</volume><fpage>237</fpage><lpage>245</lpage><year>1993</year></element-citation></ref>
<ref id="b5-ol-01-06-0951"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nacheva</surname><given-names>E</given-names></name><name><surname>Holloway</surname><given-names>T</given-names></name><name><surname>Brown</surname><given-names>K</given-names></name><name><surname>Bloxham</surname><given-names>D</given-names></name><name><surname>Green</surname><given-names>AR</given-names></name></person-group><article-title>Philadelphia-negative chronic myeloid leukaemia: detection by FISH of BCR-ABL fusion gene localized either to chromosome 9 or chromosome 22</article-title><source>Br J Haematol</source><volume>87</volume><fpage>409</fpage><lpage>412</lpage><year>1994</year></element-citation></ref>
<ref id="b6-ol-01-06-0951"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aurich</surname><given-names>J</given-names></name><name><surname>Dastugue</surname><given-names>N</given-names></name><name><surname>Duchayne</surname><given-names>E</given-names></name><name><surname>Schlaifer</surname><given-names>D</given-names></name><name><surname>Rigal-Huguet</surname><given-names>F</given-names></name><name><surname>Caballin</surname><given-names>MR</given-names></name></person-group><article-title>Location of the BCR-ABL fusion gene on the 9q34 band in two cases of Ph-positive chronic myeloid leukemia</article-title><source>Genes Chromosomes Cancer</source><volume>20</volume><fpage>148</fpage><lpage>154</lpage><year>1997</year></element-citation></ref>
<ref id="b7-ol-01-06-0951"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunel</surname><given-names>V</given-names></name><name><surname>Sainty</surname><given-names>D</given-names></name><name><surname>Costello</surname><given-names>R</given-names></name><name><surname>Mozziconacci</surname><given-names>MJ</given-names></name><name><surname>Simonetti</surname><given-names>J</given-names></name><name><surname>Arnoulet</surname><given-names>C</given-names></name><name><surname>Coignet</surname><given-names>L</given-names></name><name><surname>Bouabdallah</surname><given-names>R</given-names></name><name><surname>Gastaut</surname><given-names>JA</given-names></name><name><surname>Gabert</surname><given-names>J</given-names></name><name><surname>Lafage-Pochitaloff</surname><given-names>M</given-names></name></person-group><article-title>Translocation of BCR to chromosome 9 in a Philadelphia-negative chronic myeloid leukemia</article-title><source>Cancer Genet Cytogenet</source><volume>85</volume><fpage>82</fpage><lpage>84</lpage><year>1995</year></element-citation></ref>
<ref id="b8-ol-01-06-0951"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>WT</given-names></name><name><surname>Preisler</surname><given-names>H</given-names></name><name><surname>Szego</surname><given-names>K</given-names></name><name><surname>Sprudzs</surname><given-names>R</given-names></name><name><surname>Gao</surname><given-names>XZ</given-names></name></person-group><article-title>The ABL/BCR fusion gene on chromosome 9 in Ph-negative chronic myelogenous leukemia: a case for vigilance in fluorescence in situ hybridization interpretation</article-title><source>Cancer Genet Cytogenet</source><volume>104</volume><fpage>57</fpage><lpage>60</lpage><year>1998</year></element-citation></ref>
<ref id="b9-ol-01-06-0951"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michalova</surname><given-names>K</given-names></name><name><surname>Zemanova</surname><given-names>Z</given-names></name><name><surname>Bkezinova</surname><given-names>J</given-names></name><name><surname>Moravcova</surname><given-names>J</given-names></name><name><surname>Oltova</surname><given-names>A</given-names></name><name><surname>Sobotka</surname><given-names>J</given-names></name><name><surname>Kuglik</surname><given-names>P</given-names></name><name><surname>Kozak</surname><given-names>T</given-names></name><name><surname>Sindelarova</surname><given-names>L</given-names></name><name><surname>Jankovska</surname><given-names>M</given-names></name><name><surname>Obomilova</surname><given-names>A</given-names></name><name><surname>Sieglova</surname><given-names>Z</given-names></name><name><surname>Polak</surname><given-names>J</given-names></name><name><surname>Nadvornikova</surname><given-names>S</given-names></name><name><surname>Haskovec</surname><given-names>C</given-names></name></person-group><article-title>Location of the BCR/ABL fusion genes on both chromosomes 9q34 in Ph-negative chronic myeloid leukemia</article-title><source>Leuk Lymphoma</source><volume>43</volume><fpage>1695</fpage><lpage>1700</lpage><year>2002</year></element-citation></ref>
<ref id="b10-ol-01-06-0951"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>N</given-names></name><name><surname>Miura</surname><given-names>I</given-names></name><name><surname>Ohshima</surname><given-names>A</given-names></name><name><surname>Utsumi</surname><given-names>S</given-names></name><name><surname>Nimura</surname><given-names>T</given-names></name><name><surname>Hashimoto</surname><given-names>K</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name><name><surname>Miura</surname><given-names>AB</given-names></name></person-group><article-title>Duplication of chromosome 9 carrying a BCR/ABL chimeric gene in Philadelphia chromosome-negative chronic myeloid leukemia</article-title><source>Cancer Genet Cytogenet</source><volume>89</volume><fpage>166</fpage><lpage>169</lpage><year>1996</year></element-citation></ref>
<ref id="b11-ol-01-06-0951"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-achkar</surname><given-names>W</given-names></name><name><surname>Wafa</surname><given-names>A</given-names></name><name><surname>Nweder</surname><given-names>MS</given-names></name></person-group><article-title>A complex translocation t(5;9;22) in Philadelphia cells involving the short arm of chromosome 5 in a case of chronic myelogenous leukemia</article-title><source>J Experimental Clin Cancer Res</source><volume>26</volume><fpage>411</fpage><lpage>415</lpage><year>2007</year></element-citation></ref>
<ref id="b12-ol-01-06-0951"><label>12</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Shaffer</surname><given-names>L</given-names></name><name><surname>Slovak</surname><given-names>M</given-names></name><name><surname>Cambell</surname><given-names>L</given-names></name></person-group><source>ISCN (2009): An International System for Human Cytogenetic Nomenclature</source><publisher-name>S. Karger</publisher-name><publisher-loc>Basel</publisher-loc><year>2009</year></element-citation></ref>
<ref id="b13-ol-01-06-0951"><label>13</label><element-citation publication-type="web"><person-group person-group-type="editor"><name><surname>Mitelman</surname><given-names>F</given-names></name><name><surname>Johansson</surname><given-names>B</given-names></name><name><surname>Mertens</surname><given-names>F</given-names></name></person-group><source>Mitelman Database of Chromosome Aberrations in Cancer (2009)</source><comment><ext-link xlink:href="http://cgap.nci.nih.gov/Chromosomes/Mitelman" ext-link-type="uri">http://cgap.nci.nih.gov/Chromosomes/Mitelman</ext-link></comment></element-citation></ref>
<ref id="b14-ol-01-06-0951"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>CM</given-names></name><name><surname>Heisterkamp</surname><given-names>N</given-names></name><name><surname>Kennedy</surname><given-names>MA</given-names></name><name><surname>Fitzgerald</surname><given-names>PH</given-names></name><name><surname>Groffen</surname><given-names>J</given-names></name></person-group><article-title>Ph-negative chronic myeloid leukemia: molecular analysis of ABL insertion into M-BCR on chromosome 22</article-title><source>Blood</source><volume>76</volume><fpage>1812</fpage><lpage>1818</lpage><year>1990</year></element-citation></ref>
<ref id="b15-ol-01-06-0951"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Virgili</surname><given-names>A</given-names></name><name><surname>Brazma</surname><given-names>D</given-names></name><name><surname>Reid</surname><given-names>AG</given-names></name><name><surname>Howard-Reeves</surname><given-names>J</given-names></name><name><surname>Valga&#x000F1;&#x000F3;n</surname><given-names>M</given-names></name><name><surname>Chanalaris</surname><given-names>A</given-names></name><name><surname>De Melo</surname><given-names>VA</given-names></name><name><surname>Marin</surname><given-names>D</given-names></name><name><surname>Apperley</surname><given-names>JF</given-names></name><name><surname>Grace</surname><given-names>C</given-names></name><name><surname>Nacheva</surname><given-names>EP</given-names></name></person-group><article-title>FISH mapping of Philadelphia-negative BCR/ABL1-positive CML</article-title><source>Mol Cytogenet</source><volume>1</volume><fpage>14</fpage><year>2008</year></element-citation></ref></ref-list></back>
<floats-group>
<fig id="f1-ol-01-06-0951" position="float">
<label>Figure 1</label>
<caption>
<p>GTG-banding revealed a karyotype 46,XX.</p></caption>
<graphic xlink:href="OL-01-06-0951-g00.gif"/></fig>
<fig id="f2-ol-01-06-0951" position="float">
<label>Figure 2</label>
<caption>
<p>Karyotype and chromosomal aberrations were unconfirmed using molecular cytogenetic approaches. (A) The BCR/ABL fusion gene was absent on der(22), while the ABL/BCR fusion gene was observed on der(<xref rid="b9-ol-01-06-0951" ref-type="bibr">9</xref>). Insertion of the 3&#x02032; ABL region into the long arm on der(<xref rid="b1-ol-01-06-0951" ref-type="bibr">1</xref>) and lack of the 5&#x02032; BCR region on der(22) were noted. (B) The BCR/ABL fusion gene was absent on der(22), while the ABL/BCR fusion gene was observed on der(<xref rid="b9-ol-01-06-0951" ref-type="bibr">9</xref>). Insertion of the 3&#x02032; ABL region into the long arm on der(<xref rid="b1-ol-01-06-0951" ref-type="bibr">1</xref>) confirmed by using wcp1 and lack of the 5&#x02032; BCR region on der(22) were noted. (C) The application of FISH using wcp for chromosomes 1 and 9 did not reveal a translocation between these chromosomes. (D) The application of FISH using wcp for chromosomes 1 and 22 did not reveal a translocation between these chromosomes. &#x00023;, chromosome; der, derivative chromosome; Ph, Philadelphia-chromosome.</p></caption>
<graphic xlink:href="OL-01-06-0951-g01.gif"/></fig>
<fig id="f3-ol-01-06-0951" position="float">
<label>Figure 3</label>
<caption>
<p>Schematic representation of chromosomal changes that occurred in the patient. The BCR/ABL probe showed a fusion signal on der(<xref rid="b9-ol-01-06-0951" ref-type="bibr">9</xref>) and insertion of 3&#x02032; ABL on der(<xref rid="b1-ol-01-06-0951" ref-type="bibr">1</xref>). The 5&#x02032; region of BCR was deleted on der(22) while the 3&#x02032; region of BCR remained on chromosome 22. &#x00023;, chromosome; der, derivative chromosome.</p></caption>
<graphic xlink:href="OL-01-06-0951-g02.gif"/></fig></floats-group></article>
